Headlines
BioNTech expands UK partnership with up to $1.33 billion investment
Published by Global Banking & Finance Review®
Posted on May 20, 2025
1 min readLast updated: January 23, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on May 20, 2025
1 min readLast updated: January 23, 2026
BioNTech will invest $1.33 billion in the UK over 10 years, focusing on R&D and personalized cancer therapies, supported by a UK government grant.
(Reuters) -German vaccine maker BioNTech said on Tuesday that it plans to invest up to 1 billion pounds ($1.33 billion) over the next ten years to broaden its research and development activities in partnership with the UK government.
The company said its subsidiary BioNTech UK signed a grant agreement with the UK government that builds on a multi-year collaboration announced in January 2023.
Under the deal, BioNTech had undertaken to enroll up to 10,000 patients in clinical trials by the end of 2030 for personalized cancer therapies and make investments to expand the company's footprint in the United Kingdom.
BioNTech said on Tuesday that the UK will give the company a grant of up to 129 million pounds ($172.05 million) for a period of 10 years.
The company plans to use the grant to support its establishment of two new R&D centers, the first of which will be based in Cambridge and a second is currently being planned.
($1 = 0.7499 pounds)
(Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber)
The main topic is BioNTech's planned investment of up to $1.33 billion in the UK to expand research and development activities.
BioNTech's investment focuses on personalized cancer therapies and expanding its R&D footprint in the UK.
The UK government will provide a grant of up to 129 million pounds to BioNTech over 10 years.
Explore more articles in the Headlines category
